Highlights Newsletter 3

This newsletter presents you the following key sessions:

1. Podcast with Prof. Peter Vandenberghe about some important updates on the use of axi-cel in patients with
    relapsed/refractory diffuse large B-cell lymphoma

2. Zanubrutinib more effective than ibrutinib in the treatment of relapsed/refractory CLL with a lower rate of cardiac
    adverse events

3. High-dose methotrexate does not reduce CNS relapse in paediatric ALL

4. Significant clinical benefit with the addition of isatuximab to carfilzomib-dexamethasone in relapsed/refractory
    multiple myeloma, irrespective of the number of prior treatment lines

5. Intensive remission induction chemotherapy prior to allogeneic haematopoietic cell transplantation does not
    confer survival advantage in R/R AML